Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATB 200

Drug Profile

ATB 200

Alternative Names: AT GAA; AT-B200/AT-2220; ATB 200+chaperone; ATB-200; ATB200/AT2221; Recombinant-human-acid-alpha-glucosidase-enzyme-Amicus; rhGAA-Amicus

Latest Information Update: 31 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amicus Therapeutics
  • Class Alpha-glucosidases; Enzymes
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glycogen storage disease type II

Most Recent Events

  • 18 Dec 2019 Amicus Therapeutics initiates a phase III open label extension trial in Glycogen storage disease type II (Combination therapy) (in patients who completed ATB200-03 trial) in USA (IV) (NCT04138277)
  • 24 Oct 2019 Amicus Therapeutics plans a phase III trial for Glycogen storage disease (Pompe disease) (Combination therapy) in December 2019 (NCT04138277)
  • 02 Oct 2019 Updated efficacy, adverse events and immunogenicity data from the phase I/II ATB200-02 trial in Glycogen storage disease type II released by Amicus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top